Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Open-Label, Active-Controlled, Multicenter Phase III Safety Study of Two Doses of NATRECOR hBNP (Nesiritide) Administered as a Continuous Infusion in the Treatment of Decompensated CHF

NCT00271557 is registered in ClinicalTrials.gov with Scios, Inc. as lead sponsor.

NCT NCT00271557
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00271557 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Open-Label, Active-Controlled, Multicenter Phase III Safety Study of Two Doses of NATRECOR hBNP (Nesiritide) Administered as a Continuous Infusion in the Treatment of Decompensated CHF
Lead sponsor
Scios, Inc.
Phase
Phase 3
Overall status
Completed
Start date
January 31, 1997
Completion date
December 31, 1997
Enrollment
305 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

heart decompensation, heart failure, congestive